Eysuvis

Active Ingredient(s): Loteprednol Etabonate
FDA Approved: * October 26, 2020
Pharm Company: * KALA PHARMS INC
Category: Allergies, Cough & Cold

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Eysuvis Overview

Loteprednol (as the ester loteprednol etabonate) is a corticosteroid used to treat inflammations of the eye. It is marketed by Bausch and Lomb as Lotemax[1] and Loterex. It was patented in 1980 and approved for medical use in 1998.[2] Contents 1 Medical uses 2 Contraindications 3 Adverse effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacokinetics 5.3 Retrometabolic drug design 6 Chemistry 6.1 Chemical synthesis 7 References 8 Furt...

Read more Eysuvis Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Loteprednol

Recent Eysuvis Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Loteprednol Etabonate
  • Gel: 0.38%, 0.5%
  • Ointment: 0.5%
  • Suspension: 0.2%, 0.5%
  • Suspension/drops: 0.2%, 0.20%, 0.25%, 0.5%, 0.50%, 1%
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Loteprednol Etabonate or a similar ingredient: (5 results)